How I monitor residual disease in chronic myeloid leukemia
Open Access
- 15 October 2009
- journal article
- review article
- Published by American Society of Hematology in Blood
- Vol. 114 (16), 3376-3381
- https://doi.org/10.1182/blood-2009-02-163485
Abstract
Molecular monitoring in chronic myeloid leukemia (CML) is a powerful tool to document treatment responses and predict relapse. Nonetheless, the proliferation of clinical trials and “guidelines” using the molecular endpoints of CML has outpaced practice norms, commercial laboratory application, and reimbursement practices, leaving some anxiety (if not confusion and despair) about molecular monitoring in the day-to-day treatment of CML. This article will try to address these issues by describing how I monitor CML, which, in summary, is with interest and without panic.Keywords
This publication has 34 references indexed in Scilit:
- Monitoring treatment of chronic myeloid leukemia.Haematologica, 2008
- Mutations of the BCR-ABL-kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinibLeukemia, 2007
- Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid LeukemiaNew England Journal of Medicine, 2006
- ABL Mutations in Late Chronic Phase Chronic Myeloid Leukemia Patients With Up-Front Cytogenetic Resistance to Imatinib Are Associated With a Greater Likelihood of Progression to Blast Crisis and Shorter Survival: A Study by the GIMEMA Working Party on Chronic Myeloid LeukemiaJournal of Clinical Oncology, 2005
- Molecular Responses in Patients with Chronic Myelogenous Leukemia in Chronic Phase Treated with Imatinib MesylateClinical Cancer Research, 2005
- Monitoring patients in complete cytogenetic remission after treatment of CML in chronic phase with imatinib: patterns of residual leukaemia and prognostic factors for cytogenetic relapseLeukemia, 2005
- Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosisBlood, 2003
- HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimenBlood, 2003
- Imatinib in patients with newly diagnosed chronic-phase chronic myeloid leukemiaSeminars in Hematology, 2003
- Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid LeukemiaNew England Journal of Medicine, 2003